CERS 241220 1.00C (CERS241220C1000) Stock Options, News & Quotes

0.62
-0.18-22.50%

15min DelayClose Dec 20 16:00 ET

0.62High0.60Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Dec 9 16:05

Update! Hmm.

$Cerus (CERS.US)$ Reuters· 4 mins ago
Cerus Corp - Extends Supply and Manufacturing Agreement With Porex Until Dec 31, 2027

我要向钱看

Oct 31 01:51

$Cerus (CERS.US)$ Financial Performance:
Cerus Corporation reported Q3 product revenue of $46 million, achieving a 16% year-over-year growth. The nine-month period product revenue summed up to $129.5 million, indicating an 18% increase from the prior year.
Notable improvements in product gross margins which reached 56.9% in Q3, a rise of 200 basis points from the prior year's same period, attributed primarily to reduced product and supply chain costs.
Operating expenses in Q3 amounted to $31.8...

Jaguar8

Oct 30 15:00

NEWS

$Cerus (CERS.US)$
Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods
Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million

我要向钱看

Oct 24 21:42

UPDATES

$Cerus (CERS.US)$$Cerus (CERS.US)$ is scheduled to release its financial results post-market on October 30 ET.
Earnings Preview
Analysts estimate $Cerus (CERS.US)$ to post revenue of USD47.80M for 2024Q3, up 20.18% YOY;
EPS is estimated to be USD-0.03, Net Loss Narrowed 18.8% YoY.
The accounting standard used for the above data is US-GAAP.

我要向钱看

Oct 16 22:06

$5 TP

$Cerus (CERS.US)$ TD Cowen analyst Josh Jennings maintains $Cerus (CERS.US)$ with a buy rating, and maintains the target price at $5.